Increase in spleen volume as a predictor of oxaliplatin toxicity

Figures & data

Table 1 Characteristics of the patients

Parameters	Value	Percentage (N=50)	Total	Missing
Gender	Male	74 (n=37)	50	0
	Female	26 (n=13)
Type of cancer	Colon	50 (n=25)	50	0
	Pancreatic	22 (n=11)
	Rectal	16 (n=8)
	Gastric	12 (n=6)
Stage	IV	58 (n=29)	50	0
	III	34 (n=17)
	II	8 (n=4)
Neoadjuvant chemotherapy	FOLFOX	16 (n=8)	15	0
	FOLFIRINOX	12 (n=6)
	XELOX	2 (n=1)
Adjuvant chemotherapy	FOLFOX	40 (n=20)	35	0
	FOLFIRINOX	16 (n=8)
	XELOX	14 (n=7)
Metastasis	None	42 (n=21)	50	0
	Liver	48 (n=24)
	Lung	2 (n=1)
	Others	8 (n=4)

Table 2 Adverse events of oxaliplatin

Events	Yes, %	No, %	Missing
Increase in spleen size	74 (n=37)	24 (n=12)	1
Thrombocytopenia	10 (n=5)	88 (n=44)	1
Peripheral neuropathy	G1: 42 (n=21)	34 (n=17)	0
	G2: 20 (n=10)
	G3: 4 (n=2)
AST increase	14 (n=7)	44 (n=22)	21
ALT increase	14 (n=7)	46 (n=23)	20

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase.